Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America.
PLoS One. 2014 Mar 20;9(3):e92717. doi: 10.1371/journal.pone.0092717. eCollection 2014.
The predictors of Fanconi syndrome (FS) accompanied by renal function decline with use of the antiretroviral tenofovir disoproxil fumarate (TDF) have not been assessed. In addition, the natural history of renal recovery from FS after TDF discontinuation is not well-described.
We prospectively enrolled HIV-infected patients receiving TDF with newly identified FS (defined as at least two markers of proximal tubulopathy and either a >25% decline in creatinine clearance (CrCl) from pre-TDF values or a CrCl <60 mL/min in those without a known pre-TDF CrCl) in a multicenter observational study. These case participants were matched 1:2 to controls; characteristics between the two groups were compared. Case participants with known pre-TDF CrCl values were then followed over 48 weeks to assess renal recovery.
Nineteen cases and 37 controls were enrolled. In multivariable analysis, previous or concurrent use of lopinavir/ritonavir [OR 16.37, 95% CI (2.28, 117.68); P = 0.006] and reduced creatinine clearance prior to initiation of TDF [OR 1.44 for every 5 mL/min reduction, 95% CI (1.09, 1.92); P = 0.012; OR 19.77 for pre-TDF CrCl lower than 83 mL/min, 95% CI (2.24, 174.67); P = 0.007] were significantly associated with FS. Of the 14 cases followed for resolution, 7 (50%) achieved at least partial resolution (defined as recovering CrCl >70% of pre-TDF values) although most participants had full normalization of proximal tubulopathy markers within two months of TDF discontinuation.
FS, defined by specific CrCl decreases and markers of tubulopathy, is more likely in those who have received or are currently receiving concomitant lopinavir/ritonavir or who had lower CrCl prior to TDF initiation. Half of those with protocol-defined FS had CrCl recover to near pre-TDF values during the first year after TDF discontinuation.
尚未评估使用抗逆转录病毒药物替诺福韦二吡呋酯(TDF)时伴有肾功能下降的范可尼综合征(FS)的预测因素。此外,TDF 停药后 FS 肾功能恢复的自然史也尚未得到很好的描述。
我们前瞻性地招募了在多中心观察性研究中接受 TDF 治疗且新诊断为 FS(定义为至少有两种近端肾小管病变标志物,或 CrCl 较 TDF 治疗前降低≥25%,或在无已知 TDF 治疗前 CrCl 的情况下 CrCl<60mL/min)的 HIV 感染患者。这些病例参与者与对照组按 1:2 匹配;比较两组的特征。然后对已知 TDF 治疗前 CrCl 值的病例参与者进行 48 周的随访,以评估肾功能恢复情况。
共纳入 19 例病例和 37 例对照。多变量分析显示,先前或同时使用洛匹那韦/利托那韦[比值比(OR)16.37,95%置信区间(CI)(2.28,117.68);P=0.006]和 TDF 治疗前 CrCl 降低[OR 每降低 5mL/min 为 1.44,95%CI(1.09,1.92);P=0.012;OR 为 TDF 治疗前 CrCl 低于 83mL/min 时为 19.77,95%CI(2.24,174.67);P=0.007]与 FS 显著相关。在随访以确定 FS 缓解的 14 例病例中,7 例(50%)至少部分缓解(定义为 CrCl 恢复至 TDF 治疗前值的>70%),尽管大多数参与者在 TDF 停药后两个月内近端肾小管病变标志物完全正常化。
由特定的 CrCl 降低和肾小管病变标志物定义的 FS 更可能发生在接受或正在接受洛匹那韦/利托那韦联合治疗的患者,或 TDF 治疗前 CrCl 降低的患者。在 TDF 停药后的第一年,一半的有协议定义的 FS 患者的 CrCl 恢复到接近 TDF 治疗前的值。